company background image
BIOL

BIOLASE NasdaqCM:BIOL Stock Report

Last Price

US$4.53

Market Cap

US$26.1m

7D

-0.7%

1Y

-75.6%

Updated

24 Jun, 2022

Data

Company Financials +
BIOL fundamental analysis
Snowflake Score
Valuation3/6
Future Growth1/6
Past Performance0/6
Financial Health6/6
Dividends0/6

BIOL Stock Overview

BIOLASE, Inc., together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally.

BIOLASE Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for BIOLASE
Historical stock prices
Current Share PriceUS$4.53
52 Week HighUS$23.49
52 Week LowUS$3.30
Beta1.64
1 Month Change-5.43%
3 Month Change-48.05%
1 Year Change-75.55%
3 Year Change-87.67%
5 Year Change-96.26%
Change since IPO-99.78%

Recent News & Updates

Shareholder Returns

BIOLUS Medical EquipmentUS Market
7D-0.7%7.0%6.6%
1Y-75.6%-23.7%-18.5%

Return vs Industry: BIOL underperformed the US Medical Equipment industry which returned -25.1% over the past year.

Return vs Market: BIOL underperformed the US Market which returned -20.5% over the past year.

Price Volatility

Is BIOL's price volatile compared to industry and market?
BIOL volatility
BIOL Average Weekly Movement16.0%
Medical Equipment Industry Average Movement10.5%
Market Average Movement8.0%
10% most volatile stocks in US Market16.6%
10% least volatile stocks in US Market3.1%

Stable Share Price: BIOL is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 16% a week.

Volatility Over Time: BIOL's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
1984160John Beaverhttps://www.biolase.com

BIOLASE, Inc., together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, such as cosmetic, restorative, and complex surgical applications. The company offers Waterlase all-tissue dental laser systems for cutting soft and hard tissues; diode soft-tissue laser systems for soft tissue, pain therapy, teeth whitening, and cosmetic procedures; and Epic Hygiene laser to manage non-surgical periodontitis and enhance clinical production.

BIOLASE Fundamentals Summary

How do BIOLASE's earnings and revenue compare to its market cap?
BIOL fundamental statistics
Market CapUS$26.05m
Earnings (TTM)-US$14.26m
Revenue (TTM)US$41.24m

0.7x

P/S Ratio

-2.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
BIOL income statement (TTM)
RevenueUS$41.24m
Cost of RevenueUS$22.72m
Gross ProfitUS$18.52m
Other ExpensesUS$32.78m
Earnings-US$14.26m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-2.31
Gross Margin44.90%
Net Profit Margin-34.59%
Debt/Equity Ratio66.3%

How did BIOL perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is BIOL undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BIOL?

Other financial metrics that can be useful for relative valuation.

BIOL key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue0.5x
Enterprise Value/EBITDA-1.4x
PEG Ration/a

Price to Sales Ratio vs Peers

How does BIOL's PS Ratio compare to its peers?

BIOL PS Ratio vs Peers
The above table shows the PS ratio for BIOL vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average38.2x

Price-To-Sales vs Peers: BIOL is good value based on its Price-To-Sales Ratio (0.7x) compared to the peer average (38.2x).


Price to Earnings Ratio vs Industry

How does BIOL's PE Ratio compare vs other companies in the U.S. Medical Equipment Industry?

Price-To-Sales vs Industry: BIOL is good value based on its Price-To-Sales Ratio (0.7x) compared to the US Medical Equipment industry average (3.8x)


Price to Sales Ratio vs Fair Ratio

What is BIOL's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BIOL PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.7x
Fair PS Ratio1.2x

Price-To-Sales vs Fair Ratio: BIOL is good value based on its Price-To-Sales Ratio (0.7x) compared to the estimated Fair Price-To-Sales Ratio (1.2x).


Share Price vs Fair Value

What is the Fair Price of BIOL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate BIOL's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate BIOL's fair value for valuation analysis.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate BIOL's PEG Ratio to determine if it is good value.


Discover undervalued companies

Future Growth

How is BIOLASE forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

Future Growth Score

1/6

Future Growth Score 1/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


18.6%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: BIOL is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: BIOL is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: BIOL is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: BIOL's revenue (11% per year) is forecast to grow faster than the US market (8.3% per year).

High Growth Revenue: BIOL's revenue (11% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if BIOL's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Past Performance

How has BIOLASE performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-3.9%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: BIOL is currently unprofitable.

Growing Profit Margin: BIOL is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: BIOL is unprofitable, and losses have increased over the past 5 years at a rate of 3.9% per year.

Accelerating Growth: Unable to compare BIOL's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BIOL is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (12.9%).


Return on Equity

High ROE: BIOL has a negative Return on Equity (-68.12%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is BIOLASE's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: BIOL's short term assets ($43.8M) exceed its short term liabilities ($13.1M).

Long Term Liabilities: BIOL's short term assets ($43.8M) exceed its long term liabilities ($16.5M).


Debt to Equity History and Analysis

Debt Level: BIOL has more cash than its total debt.

Reducing Debt: BIOL had negative shareholder equity 5 years ago, but is now positive and has therefore improved.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: BIOL has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: BIOL has sufficient cash runway for 1 years if free cash flow continues to reduce at historical rates of 0.5% each year.


Discover healthy companies

Dividend

What is BIOLASE current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate BIOL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate BIOL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BIOL's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BIOL's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as BIOL has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

5.7yrs

Average management tenure


CEO

John Beaver (60 yo)

1.33yrs

Tenure

US$880,802

Compensation

Mr. John R. Beaver has been the Chief Executive Officer and President of BIOLASE, Inc. since February 23, 2021 and has been its Director since March 2021. Mr. Beaver served as the Chief Financial Officer s...


CEO Compensation Analysis

Compensation vs Market: John's total compensation ($USD880.80K) is about average for companies of similar size in the US market ($USD758.64K).

Compensation vs Earnings: John's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: BIOL's management team is seasoned and experienced (5.7 years average tenure).


Board Members

Experienced Board: BIOL's board of directors are not considered experienced ( 0.8 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.6%.


Top Shareholders

Company Information

BIOLASE, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: BIOLASE, Inc.
  • Ticker: BIOL
  • Exchange: NasdaqCM
  • Founded: 1984
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Implied Market Cap: US$26.054m
  • Shares outstanding: 6.17m
  • Website: https://www.biolase.com

Number of Employees


Location

  • BIOLASE, Inc.
  • 27042 Towne Centre Drive
  • Suite 270
  • Foothill Ranch
  • California
  • 92610-2811
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/06/24 00:00
End of Day Share Price2022/06/24 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.